Lambert-Eaton Myasthenic Syndrome (LEMS)- Pipeline Insight, 2019

"Lambert-Eaton Myasthenic Syndrome (LEMS)- Pipeline Insight, 2019" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Lambert-Eaton Myasthenic Syndrome (LEMS) pipeline landscape is provided which includes the disease overview and Lambert-Eaton Myasthenic Syndrome (LEMS) treatment guidelines. The assessment part of the report embraces, in depth Lambert-Eaton Myasthenic Syndrome (LEMS) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Lambert-Eaton Myasthenic Syndrome (LEMS) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Lambert-Eaton Myasthenic Syndrome (LEMS) Understanding
According to the Muscular Dystrophy Association, Lambert–Eaton myasthenic syndrome (LEMS) also known as Lambert-Eaton Syndrome is an autoimmune disease in which the immune system attacks the body’s own tissues. The attack occurs at the connection between nerve and muscle (the neuromuscular junction) and interferes with the ability of nerve cells to send signals to muscle cells. Specifically, the immune system attacks the calcium channels on nerve endings that are required to trigger the release of chemicals (acetylcholine). With fewer calcium channels, the nerve ending releases less acetylcholine. Acetylcholine is a chemical messenger that triggers muscle contraction. In people with LEMS, the lowered levels of acetylcholine are not sufficient to cause normal muscle contractions, causing muscle weakness. LEMS is characterized by weakness and fatigue especially of the muscles in the legs and arms. LEMS can affect many muscles, but usually, it causes weakness mostly in the upper legs and hips more than the upper arms and shoulders. These proximal muscles are more likely to fatigue with use, and muscle fatigue and sometimes stiffness may be more prominent than actual weakness. The legs are particularly affected. There may be difficulty getting out of a chair, going up stairs, running, or walking. Lifting and pushing may be difficult.
Lambert-Eaton Myasthenic Syndrome (LEMS) Pipeline Development Activities
The report provides insights into different therapeutic candidates in discovery and preclinical, phase 1, phase 2, and phase 3 stage. Drugs under development as a monotherapy or combination therapy are also included. It also analyses key players involved in Lambert-Eaton Myasthenic Syndrome (LEMS) targeted therapeutics development with respective active and inactive (dormant or discontinued) projects with the appropriate reasons if available. Lambert-Eaton Myasthenic Syndrome (LEMS) pipeline report covers 2+ companies. Some of the key players include Shenox Pharmaceuticals (SHX 003) etc.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university web sites and industry-specific third party sources, etc.
Lambert-Eaton Myasthenic Syndrome (LEMS) Analytical Perspective by DelveInsight
• In-depth Lambert-Eaton Myasthenic Syndrome Commercial Assessment of products
This report provides an in-depth Commercial Assessment of therapeutic drugs have been included which comprises of collaborations, Licensing, Acquisition –Deal Value Trends. The sub-segmentation is described in the report which includes Company-Company Collaborations (Licensing / Partnering), Company-Academia Collaborations, and Acquisition analysis in both Graphical and tabulated form.
• Lambert-Eaton Myasthenic Syndrome Clinical Assessment of products
The report comprises of comparative clinical assessment of products by development stage, product type, route of administration, molecule type, and MOA type across this indication.
Scope of the report
• The Lambert-Eaton Myasthenic Syndrome report provides an overview of therapeutic pipeline activity for Lambert-Eaton Myasthenic Syndrome across the complete product development cycle including all clinical and non-clinical stages
• It comprises of detailed profiles of Lambert-Eaton Myasthenic Syndrome therapeutic products with key coverage of developmental activities including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details
• Detailed Lambert-Eaton Myasthenic Syndrome Research and Development progress and trial details, results wherever available, are also included in the pipeline study
• Therapeutic assessment of the active pipeline products by development stage, product type, route of administration, molecule type, and MOA type
• Coverage of dormant and discontinued pipeline projects along with the reasons if available across Lambert-Eaton Myasthenic Syndrome
Reasons to Buy
• Establish a comprehensive understanding of the current pipeline scenario across Lambert-Eaton Myasthenic Syndrome to formulate effective R&D strategies
• Assess challenges and opportunities that influence Lambert-Eaton Myasthenic Syndrome R&D
• Develop strategic initiatives by understanding the focus areas of leading companies.
• Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
• Get in detail information of each product with updated information on each project along with key milestones
• Devise Lambert-Eaton Myasthenic Syndrome in licensing and out licensing strategies by identifying prospective partners with progressing projects for Lambert-Eaton Myasthenic Syndrome to enhance and expand business potential and scope
• Our extensive domain knowledge on therapy areas support the clients in decision-making process regarding their therapeutic portfolio by identifying the reason behind the inactive or discontinued drugs